| Autor: |
Veljkovic, Nevena, Vucicevic, Jelica, Tassini, Sabrina, Glisic, Sanja, Veljkovic, Veljko, Radi, Marco |
| Zdroj: |
Expert Opinion on Drug Discovery; June 2014, Vol. 10 Issue: 6 p671-684, 14p |
| Abstrakt: |
Introduction:Maraviroc is a first-in-class antiretroviral (ARV) drug acting on a host cell target (CCR5), which blocks the entry of the HIV virus into the cell. Maraviroc is currently indicated for combination ARV treatment in adults infected only with CCR5-tropic HIV-1.Areas covered:This drug discovery case history focuses on the key studies that led to the discovery and approval of maraviroc, as well as on post-launch clinical reports. The article is based on the data reported in published preclinical and clinical studies, conference posters and on drug package data.Expert opinion:The profound understanding of HIV’s entry mechanisms has provided a strong biological rationale for targeting the chemokine receptor CCR5. The CCR5-antagonist mariviroc, with its unique mode of action and excellent safety profile, is an important therapeutic option for HIV patients. In general, the authors believe that targeting host factors is a useful approach for combating new and re-emerging transmissible diseases, as well as pathogens that easily become resistant to common antiviral drugs. Maraviroc, offering a potent and safe cellular receptor-mediated pharmacological response to HIV, has paved the way for the development of a new generation of host-targeting antivirals. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
